microRNA-130a (miR-130a)

microRNA-130a (miR-130a) is a highly conserved small non-coding RNA molecule that plays a critical role in the post-transcriptional regulation of gene expression by binding to the 3' untranslated regions (UTRs) of target messenger RNAs (mRNAs) [PMID: 23536000]. It is a key regulator of vascular biology, particularly in modulating angiogenesis through the targeting of Homeobox A5 (HOXA5) and Vascular Endothelial Growth Factor (VEGF) pathways [PMID: 18511639]. In oncology, miR-130a exhibits a dual role, acting as an oncomir in some contexts, such as gastric and breast cancers, while functioning as a tumor suppressor in others, like lung cancer, by influencing cell proliferation, migration, and apoptosis [PMID: 25673474]. Beyond cancer, it is significantly involved in the pathogenesis of cardiovascular diseases, including pulmonary arterial hypertension and atherosclerosis, as well as liver fibrosis [PMID: 27433108]. Therapeutic targeting of miR-130a involves the use of synthetic miRNA mimics to restore its function or antagomirs (antisense oligonucleotides) to inhibit its activity, depending on the disease state [PMID: 30233456]. While no miR-130a-specific therapies are currently FDA-approved, it remains a major focus of clinical research due to its broad regulatory influence and potential as a diagnostic biomarker [PMID: 31431704].

Other names

MIR130Ahsa-miR-130amicroRNA 130a-3pmicroRNA 130a-5p

Antisense oligonucleotide-mediated inhibition of microRNA activity or synthetic double-stranded RNA-mediated restoration of microRNA function